10-Q: Xeris Biopharma Reports Q1 2026 Financial Results

Xeris Biopharma Holdings, Inc. announced its first quarter 2026 financial results, showcasing significant revenue growth driven by Recorlev, while managing operational expenses and focusing on pipeline development.

Summary

• Xeris Biopharma Holdings, Inc. reported total revenue of $83.1 million for the first quarter ended March 31, 2026, a 38.3% increase compared to $60.1 million in the same period of 2025.
• Net income for the quarter was $2.2 million, a significant improvement from a net loss of $9.2 million in Q1 2025.
• Product revenue, net, increased by 42.6% to $82.5 million, primarily driven by a 94.9% surge in Recorlev revenue.
• Cost of goods sold increased by 21.2% to $10.6 million, but improved as a percentage of revenue.
• Research and development expenses rose by 13.3% to $8.8 million, with a notable increase in personnel-related expenses.
• Selling, general, and administrative expenses increased by 20.7% to $53.1 million, largely due to higher personnel costs supporting commercial expansion.
• The company ended the quarter with $111.8 million in cash and cash equivalents.
• Xeris Biopharma is actively defending its patents for Recorlev against generic drug applications.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report due to significant revenue growth and a return to profitability, although the company's accumulated deficit and potential future financing needs temper the overall sentiment.

Positives

• Total revenue increased by 38.3% to $83.1 million in Q1 2026 compared to Q1 2025.
• Recorlev revenue saw a substantial increase of 94.9% to $49.8 million, indicating strong market adoption and demand.
• The company achieved net income of $2.2 million in Q1 2026, a significant turnaround from a net loss of $9.2 million in Q1 2025.
• Cost of goods sold as a percentage of total revenue improved to 12.8% from 15.1% year-over-year.
• Cash and cash equivalents remained strong at $111.8 million as of March 31, 2026.
• The company has a robust patent portfolio, with 181 patents issued globally, including those protecting Recorlev until 2040.

Negatives

• Royalty, contract and other revenue decreased by 71.0% to $0.7 million, primarily due to the absence of a milestone payment recognized in the prior year.
• Selling, general, and administrative expenses increased by 20.7% to $53.1 million, reflecting increased investment in commercial operations.
• The company has an accumulated deficit of $669.1 million as of March 31, 2026.
• The company may need to seek additional financing in the future, with no assurance of availability on acceptable terms.

Risks

• The company is subject to risks similar to other specialty pharmaceutical companies, including successful commercialization and market acceptance of products, development of new technological innovations by competitors, ability to acquire additional capital, and protection of intellectual property.
• Disruptions from single-source suppliers or manufacturers could negatively impact the company's business.
• Geopolitical and macroeconomic events and conditions pose risks.
• The company faces patent infringement lawsuits related to Recorlev, with potential for automatic stays on FDA approval of generic versions.
• The company may not be profitable even if it commercializes its product candidates.
• Future capital requirements depend on commercialization success, clinical trial costs, regulatory reviews, competition, and intellectual property defense.

Future Outlook

The company believes its current cash resources are sufficient for at least the next twelve months. However, it anticipates incurring substantial expenditures to support commercialization and R&D, and may require additional financing. Future capital needs depend on commercial success, clinical trial outcomes, regulatory actions, competition, and intellectual property defense.

Management Comments

• The company's strategy is to continue building a profitable biopharmaceutical company focused on developing and commercializing therapies for chronic endocrine and neurological diseases.
• Xeris is uniquely positioned to execute this strategy through the continued growth of its three commercial products, enabling investment in therapies for unmet medical needs.
• The company believes this strategy will generate value for all stakeholders.

Industry Context

StockSavvy.ai notes that Xeris Biopharma's Q1 2026 results reflect a biopharmaceutical company navigating the challenges of commercializing specialized therapies while managing R&D investments. The significant revenue growth from Recorlev highlights successful market penetration, a key indicator in this competitive sector. The ongoing patent litigation is a common occurrence in the industry, underscoring the importance of intellectual property protection.

Comparison to Industry Standards

• The revenue growth of 42.6% for total revenue and 94.9% for Recorlev in Q1 2026 significantly outpaces the average growth rates for many established pharmaceutical companies, which typically see single-digit or low double-digit growth.
• The shift to profitability with a $2.2 million net income in Q1 2026, compared to a loss in the prior year, is a positive indicator, though the company still carries a substantial accumulated deficit. Many biopharma companies in the development or early commercialization phase operate at a loss for extended periods.
• The SG&A expense increase of 20.7% is in line with companies expanding commercial efforts for key products, a necessary investment for market share growth.
• The R&D spend increase of 13.3% aligns with industry practices for companies advancing pipeline candidates, such as Xeris's XP-8121.

Legal Proceedings

• Patent infringement lawsuits filed against Torrent Pharmaceuticals, Somerset Therapeutics, Sandoz, and Zydus Lifesciences regarding generic versions of Recorlev.
• The lawsuits allege infringement of four Orange Book-listed patents for Recorlev, scheduled to expire in March 2040.
• The company seeks injunctions to prevent FDA approval of ANDAs and commercialization of generic Recorlev until patent expiration.
• The filing of these lawsuits triggered an automatic 30-month stay on FDA approval of the ANDAs.
• The company may face additional patent infringement lawsuits in the future.
• Management is not aware of any other existing, pending, or threatened legal actions that would have a material impact on the financial position or results of operations.

Stakeholder Impact

• Shareholders may benefit from the significant revenue growth and return to profitability, but face risks associated with the company's accumulated deficit and potential future financing needs.
• Employees may see continued investment in R&D and commercial expansion, potentially leading to growth opportunities.
• Customers (patients) benefit from the availability of therapies for chronic endocrine and neurological diseases.
• Suppliers may experience increased demand due to higher product sales, but face risks related to potential disruptions from single-source suppliers.
• Creditors face risks related to the company's substantial debt and accumulated deficit, though the company believes its current cash is sufficient for the next twelve months.

Next Steps

• Initiate Phase 3 clinical trial for XP-8121 (once-weekly subcutaneous levothyroxine).
• Continue pursuing formulation and development partnerships.
• Continue selling and marketing efforts for Recorlev, Gvoke, and Keveyis.
• Continue research and development efforts.
• Continue to operate as a public company.
• Continue to fund operations with potential increased cost of borrowing.
• Potentially seek public equity and debt financing.

Key Dates

Recommendation

The company shows strong revenue growth and a positive shift to profitability, driven by Recorlev. However, the significant accumulated deficit, ongoing patent litigation, and the potential need for future financing introduce considerable risk. A 'hold' recommendation reflects a balanced view, awaiting further clarity on pipeline progression, patent defense outcomes, and sustainable profitability before considering a more aggressive stance.

Keywords

Xeris Biopharma, Form 10-Q, Quarterly Report, Recorlev, Gvoke, Keveyis, Biopharmaceutical, Financial Results, Revenue Growth, Patent Infringement, Cushing's Syndrome, Hypoglycemia, Primary Periodic Paralysis